Not prescribed
Thus, it has been investigated thoroughly as an agent for increasing tolerance to sunlight in several conditions: Polymorphic light eruption (abnormal immune reaction and rash due to sunlight/UV exposure): Phase 3 studies show that MT1 reduces the severity of polymorphic light eruption rashes triggered by sunlight exposure when administered as a 16mg implant for four months [9]
GLP-1 Pipeline Update: February 2025, Prime Therapeutics, 2025
Across various trials, the most common side effects have been mild gastrointestinal issues: nausea, vomiting, or diarrhea
It was very uncomfortable
Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, et al